Live From JPM 2026: Is This the End of American Biotech Leadership?

The race is being won by someone else. While the headlines focus on the prestige of JPM 2026, a much quieter and more dangerous shift is happening behind the scenes. In this special edition of The Making Medicine Podcast, John Stanford sits down with Terzel Vasquez of STAT Brand Studio to discuss why the American biotech engine is beginning to stall. Stanford argues that capital flows like water, and right now, poorly designed Washington policies are acting like boulders in the stream, forcing vital investment away from life-saving small molecules and rare disease research.The conversation pulls back the curtain on a massive cognitive dissonance in modern policy. By attacking the end of the value chain, specifically the large manufacturers who bring drugs to the finish line, lawmakers are inadvertently starving the early-stage startups they claim to protect. From the Pill Penalty to the looming shadow of China’s bio-dominance, this episode explores why biotech has officially moved from a healthcare issue to a critical national security prerogative. Join the ConversationIs U.S. biotech leadership still a "national security priority," or have we already ceded the lead?If “unintended consequences" force a choice between a $100,000 injectable biologic and a $200 oral pill that never gets funded, who actually wins?Is Washington "fixing" the price of medicine, or just distracting us from a broken insurance system?If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:https://x.com/MakingMedPodhttps://www.instagram.com/makingmedicinepod/https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=trueTimestamps0:00  Policy Warning & Headlines 0:23  JPM 2026: Incubate Briefing 0:36  Capital Flight: Policy Barriers 1:24  The IRA "Pill Penalty" 2:22  Rare Disease Funding Gap 2:32  The $1 Billion Fix 3:18  The Innovation Relay Race 4:24  The Movie Studio Paradox 5:28  China’s "Green Light" Strategy 6:58  Biotech: National Security Asset 9:20  The $3 Billion Drug Cost 10:18  Insurance Breakdown & Access 11:36  Fixing the Root IssueDISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.